Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.

Alves, Carla L; Ehmsen, Sidse; Terp, Mikkel G; Portman, Neil; Tuttolomondo, Martina; Gammelgaard, Odd L; Hundebøl, Monique F; Kaminska, Kamila; Johansen, Lene E; Bak, Martin; Honeth, Gabriella; Bosch, Ana; Lim, Elgene; Ditzel, Henrik J

Alves, Carla L; Ehmsen, Sidse; Terp, Mikkel G; Portman, Neil; Tuttolomondo, Martina; Gammelgaard, Odd L; Hundebøl, Monique F; Kaminska, Kamila; Johansen, Lene E; Bak, Martin; Honeth, Gabriella; Bosch, Ana; Lim, Elgene; Ditzel, Henrik J.

Afiliación

Alves CL; Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark. calves@health.sdu.dk.
Ehmsen S; Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Terp MG; Department of Oncology, Institute of Clinical Research, Odense University Hospital, Odense, Denmark.
Portman N; Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Tuttolomondo M; Garvan Institute of Medical Research, Sydney, NSW, Australia.
Gammelgaard OL; St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales Sydney, Sydney, NSW, Australia.
Hundebøl MF; Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Kaminska K; Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Johansen LE; Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Bak M; Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.
Honeth G; Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Bosch A; Department of Pathology, Sydvestjysk Sygehus, Esbjerg, Denmark.
Lim E; Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.
Ditzel HJ; Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.

Nat Commun ; 12(1): 5112, 2021 08 25.

Article en En | MEDLINE | ID: mdl-34433817

Asunto(s)

Neoplasias de la Mama/tratamiento farmacológico; Quinasa 4 Dependiente de la Ciclina/antagonistas & inhibidores; Quinasa 6 Dependiente de la Ciclina/antagonistas & inhibidores; Fulvestrant/administración & dosificación; Inhibidores de Proteínas Quinasas/administración & dosificación; Proteínas Proto-Oncogénicas c-akt/metabolismo; Neoplasias de la Mama/enzimología; Neoplasias de la Mama/genética; Línea Celular Tumoral; Quinasa 4 Dependiente de la Ciclina/genética; Quinasa 4 Dependiente de la Ciclina/metabolismo; Quinasa 6 Dependiente de la Ciclina/genética; Quinasa 6 Dependiente de la Ciclina/metabolismo; Progresión de la Enfermedad; Resistencia a Antineoplásicos; Quimioterapia Combinada; Femenino; Humanos; Terapia Molecular Dirigida; Proteínas Proto-Oncogénicas c-akt/genética

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Inhibidores de Proteínas Quinasas / Quinasa 4 Dependiente de la Ciclina / Quinasa 6 Dependiente de la Ciclina / Proteínas Proto-Oncogénicas c-akt / Fulvestrant Límite: Female / Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2021 Tipo del documento: Article País de afiliación: Dinamarca

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google